Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
In this retrospective analysis, anlotinib combined with taxane/capecitabine demonstrated a manageable safety profile. This regimen was associated with improved DCR, PFS, and OS compared to bevacizumab plus chemotherapy in patients with HER2-negative MBC. These findings suggest that anlotinib may represent a promising therapeutic option for patients for whom ADC drugs are inaccessible or unsuitable; however, further prospective, randomized studies are warranted to confirm.
Authors
- Jiannan Liu
- Lei Song (ORCID: https://orcid.org/0000-0002-9695-1737)
- Jinyu Xiang (ORCID: https://orcid.org/0000-0003-4698-5717)
- Zeyu Liu (ORCID: https://orcid.org/0000-0003-4377-1780)
- Ping Sun
- Qingyu Zhang (ORCID: https://orcid.org/0000-0001-9739-3899)
Institutions
- Yuhuangding Hospital (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/dddt.s548425
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China